Astrazeneca Plc · LSE:AZN
Astrazeneca — Shareholder Meeting (2009)
40 slides from Astrazeneca's shareholder meeting presentation, 2009
Slide 1: AstraZeneca
AstraZeneca
Slide 2: Louis Schweitzer, Chairman
Astrazeneca? Louis Schweitzer Chairman
Slide 3: Board Members
Board Members
Slide 4: Board Members
Board Members
Slide 5: Board Members
Board Members
Slide 6: AstraZeneca
AstraZeneca
Slide 7: Headline results: Full Year 2008
Headline results: Full Year 2008 2008 2007 Actual CER $m $m growth growth Sales 31,601 29,559 +7% +3% Core Operating Profit 10,958 9,411 +16% +9% Core EPS $5.10 $4.38 +16% +8% 11 medicines with annual sales of more than $1 billion Net debt reduced by $1.9 billion Returned $3.35 billion to shar
Slide 8: AstraZeneca
AstraZeneca
Slide 9: David Brennan, CEO
David Brennan CEO
Slide 10: Strategic priorities
Strategic priorities “MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES” Grow Reshape Change our Strengthen behaviour the the the pipeline business and our business culture OUR VALUES
Slide 11: Headline results: Q1 2009
Headline results: Q1 2009 2009 2008 Actual CER $m $m growth growth Sales 7,701 7,677 - +7% Core Operating Profit 3,362 2,765 +22% +19% Core EPS $1.58 $1.28 +24% +20% Reported EPS $1.48 $1.03 +44% +39%
Slide 12: Headline results: Full Year 2008
Headline results: Full Year 2008 2008 2007 Actual CER $m $m growth growth Sales 31,601 29,559 +7% +3% Core Operating Profit 10,958 9,411 +16% +9% Core EPS $5.10 $4.38 +16% +8% Reported EPS $4.20 $3.74 +12% +2%
Slide 13: Strong growth in emerging markets
Strong growth in emerging markets 2008 Sales North America 2008 CER Sales Growth Established RoW 60 Emerging Markets $557m 50 40 +2% +2% % $14,785m $12,543m 30 $237m $235m 20 +16% 23% 23% 54% 10 $4,273m 0
Slide 14: AstraZeneca
AstraZeneca
Slide 15: Strengthening the pipeline
Strengthening the pipeline 137 144 Clinical projects increased 120 106 by 60% 91 Clinical Phase III/Registration doubled Phase II portfolio increased by >50% in 2008 Pre-clinical Up to 4 new product filings planned for 2009 Pre-clinical Phase I Phase II Phase III/Reg LCM
Slide 16: AstraZeneca
AstraZeneca
Slide 17: Resolution 1: Receive Accounts and Reports
Resolution 1 To receive the Company’s Accounts and the Report of the Directors and Auditor for the year ended 31 December 2008
Slide 18: Resolution 2: Confirm dividends
Resolution 2 To confirm dividends
Slide 19: Resolution 3: Re-appoint KPMG Audit Plc as Auditor
Resolution 3 To re-appoint KPMG Audit Plc, London as Auditor
Slide 20: Resolution 4: Authorise Directors to agree Auditor remuneration
Resolution 4 To authorise the Directors to agree the remuneration of the Auditor
Slide 21: Resolution 5(a): Re-elect Louis Schweitzer
Resolution 5(a) To re-elect Louis Schweitzer as a Director
Slide 22: Resolution 5(b): Re-elect David Brennan
Resolution 5(b) To re-elect David Brennan as a Director
Slide 23: Resolution 5(c): Re-elect Simon Lowth
Resolution 5(c) To re-elect Simon Lowth as a Director
Slide 24: Resolution 5(d): Re-elect Bo Angelin
Resolution 5(d) To re-elect Bo Angelin as a Director
Slide 25: Resolution 5(e): Re-elect John Buchanan
Resolution 5(e) To re-elect John Buchanan as a Director
Slide 26: Resolution 5(f): Re-elect Jean-Philippe Courtois
Resolution 5(f) To re-elect Jean-Philippe Courtois as a Director
Slide 27: Resolution 5(g): Re-elect Jane Henney
Resolution 5(g) To re-elect Jane Henney as a Director
Slide 28: Resolution 5(h): Re-elect Michele Hooper
Resolution 5(h) To re-elect Michele Hooper as a Director
Slide 29: Resolution 5(i): Re-elect Rudy Markham
Resolution 5(i) To re-elect Rudy Markham as a Director
Slide 30: Resolution 5(j): Re-elect Dame Nancy Rothwell
Resolution 5(j) To re-elect Dame Nancy Rothwell as a Director
Slide 31: Resolution 5(k): Re-elect John Varley
Resolution 5(k) To re-elect John Varley as a Director
Slide 32: Resolution 5(l): Re-elect Marcus Wallenberg
Resolution 5(l) To re-elect Marcus Wallenberg as a Director
Slide 33: Resolution 6: Approve Directors' Remuneration Report
Resolution 6 To approve the Directors’ Remuneration Report for the year ended 31 December 2008
Slide 34: Resolution 7: Authorise limited EU political donations
Resolution 7 To authorise limited EU political donations
Slide 35: Resolution 8: Authorise Directors to allot unissued shares
Resolution 8 To authorise the Directors to allot unissued shares
Slide 36: Resolution 9: Disapply pre-emption rights
Resolution 9 (Special Resolution) To authorise the Directors to disapply pre-emption rights
Slide 37: Resolution 10: Authorise purchase of own shares
Resolution 10 (Special Resolution) To authorise the Company to purchase its own shares
Slide 38: AstraZeneca
AstraZeneca
Slide 39: AstraZeneca
AstraZeneca
Slide 40: AstraZeneca
Astrazeneca